证券日报网讯 1月15日，健康元在互动平台回答投资者提问时表示，公司积极参与JPM等全球医药行业 盛会，密切关注包括脑机接口在内的前沿科技发展动态与行业趋势。相关领域的技术布局将结合公司战 略发展需要审慎研究推进，后续如有实质性进展，公司会及时履行信息披露义务。公司流感创新药壹立 康的医院准入工作正按计划有序推进，目前正积极联动各地渠道与医疗机构，全力加速药品入院落地， 确保药品快速触达临床，更好地满足患者的用药需求。 （文章来源：证券日报） ...

证券日报网讯 1月15日，健康元在互动平台回答投资者提问时表示，公司正积极与行业头部机构开展AI 咨询领域的合作探索，结合行业前沿技术与公司医药资源优势，推动AI技术在健康管理等场景的落地 应用。后续若有实质性业务布局或合作进展，公司将严格按照相关规定及时履行信息披露义务。 （编辑 王雪儿） ...

证券日报网讯 1月15日，健康元在互动平台回答投资者提问时表示，壹立康的定价核心原则是兼顾药物 创新价值与患者可及性，希望以更亲民的价格让更多流感患者受益。关于医保谈判相关事宜，公司正积 极关注政策动态并推进相关筹备工作，后续若参与谈判，价格调整将严格遵循医保谈判规则，结合政策 要求、市场情况及患者需求综合确定。未来，公司将持续以患者为中心，通过合理定价与渠道拓展，让 药品惠及更多人群。 （编辑 楚丽君） ...

（编辑 王雪儿） 证券日报网讯 1月15日，健康元在互动平台回答投资者提问时表示，公司在AI赋能医药创新领域已迈出 坚实步伐，与腾讯量子实验室的合作取得阶段性成果，双方联合开发的基于深度学习的生物合成基因簇 预测算法架构，相关研究论文已正式发布并共同申请国家发明专利，为AI技术在原料药研发、合成生 物学等核心业务场景的落地提供了重要技术支撑。未来，公司将持续加大AI技术的研发投入与应用探 索力度，聚焦AI在药物分子设计、靶点发现、工艺优化、生产效率提升等关键环节的深度融合，积极 挖掘前沿技术与核心业务的协同价值，全力推动医药研发与产业运营的智能化升级。关于与英伟达的业 务往来，公司目前暂无相关合作及计划，后续若有符合公司战略的合作机会，将积极评估推进。 ...

证券日报网讯 1月15日，健康元在互动平台回答投资者提问时表示，公司始终密切关注汇率走势，积极 运用外汇衍生品等工具，并结合优化结算货币、合理规划外币收支等方式，对冲汇率波动风险，降低汇 兑损益。 （编辑 丛可心） ...

（编辑 丛可心） 证券日报网讯 1月15日，健康元在互动平台回答投资者提问时表示，新元素药业上市尚处于流程推进阶 段，后续进展及潜在价值受市场环境、行业趋势等多重因素影响，存在不确定性，暂无法准确预估。公 司始终秉持长期主义投资理念，聚焦核心战略精选优质标的，新元素药业是公司产业链相关投资的布局 之一。未来，公司将继续砥砺前行，审慎推进各项投资与经营工作，持续为股东创造长期价值。 ...

格隆汇1月15日丨健康元(600380.SH)在投资者互动平台表示，公司在 AI 赋能医药创新领域已迈出坚实 步伐，与腾讯量子实验室的合作取得阶段性成果，双方联合开发的基于深度学习的生物合成基因簇预测 算法架构，相关研究论文已正式发布并共同申请国家发明专利，为 AI 技术在原料药研发、合成生物学 等核心业务场景的落地提供了重要技术支撑。未来，公司将持续加大 AI 技术的研发投入与应用探索力 度，聚焦 AI 在药物分子设计、靶点发现、工艺优化、生产效率提升等关键环节的深度融合，积极挖掘 前沿技术与核心业务的协同价值，全力推动医药研发与产业运营的智能化升级。关于与英伟达的业务往 来，公司目前暂无相关合作及计划，后续若有符合公司战略的合作机会，将积极评估推进。请投资者以 公司公告及官方信息为准，注意投资风险，理性投资。 ...

Group 1 - Health元's stock price increased by 0.99% to 12.21 yuan per share, with a total market capitalization of 22.338 billion yuan and a trading volume of 3.79 billion yuan, marking a cumulative increase of 5.71% over the past seven days [1] - The company, founded on December 18, 1992, and listed on June 8, 2001, operates as a comprehensive pharmaceutical enterprise engaged in the research, development, and production of traditional Chinese medicine, health products, and Western medicine [1] - The main business revenue composition includes: chemical preparations 47.71%, chemical raw materials and intermediates 31.97%, traditional Chinese medicine preparations 10.28%, diagnostic reagents and equipment 4.74%, health food 3.08%, biological products 1.20%, and others 0.86% [1] Group 2 - Longxin Fund has one fund heavily invested in Health元, with Longxin Medical Health Mixed (LOF) A (163001) reducing its holdings by 57,600 shares in the third quarter, now holding 236,000 shares, representing 2.18% of the fund's net value [2] - The fund has generated a floating profit of approximately 28,300 yuan today and a total of 155,800 yuan during the seven-day increase [2] - Longxin Medical Health Mixed (LOF) A (163001) was established on March 26, 2010, with a current scale of 128 million yuan, yielding 8.03% this year and 33.13% over the past year [2]

Group 1 - The core viewpoint of the article highlights that 2023 may be a breakout year for AI for Science (AI4S), driven by significant advancements in capabilities that allow for more extensive scientific research [1] - AI4S is now recognized as a strategic battleground among global tech giants, moving beyond the "proof of concept" stage in laboratories [1] - AI4S is aiding scientists in efficiently identifying new research opportunities, such as predicting protein functions, designing new materials, and discovering new targets [1] Group 2 - Related A-share concept stocks mentioned include Health元 and Northeast Pharmaceutical [2]

Core Viewpoint - Health元's subsidiary, Zhuhai Lizhu Biotech Co., Ltd., has announced that its product, Lakanqita monoclonal injection, has been included in the priority review and approval process as of December 26, 2025, marking its entry into the priority review stage for drug marketing authorization [1] Group 1 - The drug is intended for adult patients with moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy [1] - Lakanqita monoclonal injection is the first domestically developed and the second globally in progress IL-17A/F dual-target inhibitor [1] - The clinical trial, which was multi-center, randomized, double-blind, and positive-controlled, was completed in July 2025, showing that the drug is more effective than the comparator, Secukinumab, with good safety [1] Group 2 - Although the drug application has been accepted, it still requires evaluation and on-site inspection, leaving uncertainty regarding the final approval and market launch timing [1]